Newleos Therapeutics has dosed the first participant in its Phase Ib clinical study evaluating NTX-2001, a partial agonist of TAAR1, for AUD.

An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned in schizophrenia.

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed benefit as a second-line therapy in a Phase III ...

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Martin Makary, commissioner of the Food and Drug Administration (FDA) announces plans to cut the time it takes drug companies to test new medicines by getting more visibility into clinical trials as ...

Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

If approved, Veradermics' VDPHL01 could become the first hair loss drug to secure the regulatory go-ahead in nearly three decades.

Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) combination therapy met one key secondary endpoint but miss ...

While the drug has not been investigated in a head-to-head weight loss trial, data suggest that Lilly's Zepbound is more effective than Boehringer's survodutide.

Argo Biopharma has dosed the first subject in its Phase I clinical trial assessing BW-50218, a siRNA therapeutic targeting the TTR protein.

Massive Bio and OpenAI are to expand access to clinical studies via AI-driven protocol parameterisation and real-time patient pre-screening.

EnteroBiotix's James McIlroy says EBX-102-02 could address treatment gaps in IBS, which impacts up to 10% of the global population.